Preferred Label : mavacamten;
Origin ID : M000644816;
Currated CISMeF NLP mapping
- Related record
- MYK-461 [MeSH Supplementary Concept]
- Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-marr/mavacamten
2025
false
false
false
France
French
risk management
mavacamten
mavacamten
mavacamten
administration, oral
patients guideline
guidelines for drug use
fetus
pregnancy
embryo
drug interactions
heart failure, systolic
Fetal exposure to drug (situation)
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP3A4 Inhibitors
Cytochrome P450 family 2 subfamily C member 19 intermediate metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 ultra-rapid metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 poor metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 normal metabolizer (finding)
patient education handout
---
https://www.has-sante.fr/jcms/p_3470375/fr/camzyos-mavacamten-cardiomyopathie-hypertrophique-obstructive
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
mavacamten
administration, oral
New York Heart Association Class II
New York Heart Association Class III
adult
symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic
cardiomyopathy (oHCM)
evaluation of the transparency committee
cardiomyopathy, hypertrophic
mavacamten
Cardiomyopathy, Hypertrophic Obstructive
---
https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
mavacamten
mavacamten
drug approval
europe
mavacamten
cardiomyopathy, hypertrophic
Cardiomyopathy, Hypertrophic Obstructive
adult
administration, oral
continuity of patient care
product surveillance, postmarketing
New York Heart Association Class II
New York Heart Association Class III
CYP2C19 slow metabolizer status
Cytochrome P-450 CYP2C19
Cytochrome P450 family 2 subfamily C member 19 normal metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 rapid metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 intermediate metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 ultra-rapid metabolizer (finding)
Left Ventricular Ejection Fraction
drug interactions
pregnancy
Female of Childbearing Potential
cardiac myosins
drug evaluation, preclinical
symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic
cardiomyopathy (oHCM)
---
https://www.has-sante.fr/jcms/p_3465194/fr/camzyos-mavacamten-cardiomyopathie-hypertrophique-obstructive
2023
false
false
false
France
mavacamten
New York Heart Association Class II
New York Heart Association Class III
adult
guidelines for drug use
administration, oral
evaluation of the transparency committee
cardiomyopathy, hypertrophic
mavacamten
Cardiomyopathy, Hypertrophic Obstructive
---
https://www.cadth.ca/fr/mavacamten
2022
false
false
false
Canada
French
English
canada
insurance, health, reimbursement
mavacamten
drug evaluation
Cardiomyopathy, Hypertrophic Obstructive
adult
---
